Anales de la RANM

59 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 HISTORIA DE LOS FÁRMACOS ANTIARRÍTMICOS Tamargo Menéndez J An RANM. 2025;142(01): 51 - 60 DECLARACIÓN DE TRANSPARENCIA El autor/a de este artículo declara no tener ningún tipo de conflicto de intereses respecto a lo expuesto en el presente trabajo. BIBLIOGRAFÍA 1. Van Gelder IC, Rienstra M, Bunting KV, et al; ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fi- brillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2024;45:3314- 3414. 2. Cheng S, He J, Han Y, Han S, Li P, Liao H, Guo J. Global burden of atrial fibrillation/atrial flutter and its attributable risk factors from 1990 to 2021. Europace 2024;26:euae195. 3. Gómez-Doblas JJ, Muñiz J, Martin JJ, et al.; OFRECE study collaborators. Prevalence of atrial fibrillation in Spain. OFRECE study re- sults. Rev Esp Cardiol (Engl Ed) 2014;67:259- 269. 4. Instituo Nacional de Estadística. https://www. ine.es/dyngs/INEbase/es/operacion.htm?c=E stadistica_C&cid=1254736176780&menu=res ultados&idp=1254735573175 5. Schuijt E, Scherr D, Plank G, Schotten U, Hei- jman J. Evolution in electrophysiology 100 years after Einthoven: translational and com- putational innovations in rhythm control of atrial fibrillation. Europace 2025;27:euae304. 6. Martínez-Rubio A, Tamargo J, Dan G-A. An- tiarrhythmic drugs. 2nd Edition. Springer, 2024:1-530. 7. Levy R. Clinical studies of quinidin. II. Alte- rations in the cardiac mechanism after admi- nistration of quinidin to patients with auricu- lar fibrillation with consideration of certain toxic effects of the drug. Arch Intern Med 1922;30:451-477. 8. White PD. Heart Disease. The Macmillan Company; New York, New York: 1931. 9. Echt DS, Liebson PR, Mitchell LB, et al. Mor- tality and morbidity in patients receiving en- cainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-788. 10. Selzer A, Wray HW. Quinidine syncope. paro- xysmal ventricular fibrillation occurring du- ring treatment of chronic atrial arrhythmias. Circulation. 1964l;30:17-26. 11. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990;82:1106-1116. 12. Teo KK, Yusuf S, Furberg CD. Effects of pro- phylactic antiarrhythmic drug therapy in acu- te myocardial infarction. An overview of re- sults from randomized controlled trials. JAMA 1993;270:1589-1595. 13. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after re- cent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d- Sotalol. Lancet 1996;348:7-12. 14. Southworth MR, Zarembski D, Viana M, Bauman J. Comparison of sotalol versus quinidine for maintenance of normal sinus rhythm in patients with chronic atrial fibri- llation. Am J Cardiol 1999;83:1629-1632. 15. Yap YG, Behr ER, Camm AJ. Drug-induced Brugada syndrome. Europace 2009;11:989– 994. 16. Lafuente-Lafuente C, Valembois L, Berg- mann JF, Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardiover- sion of atrial fibrillation. Cochrane Database Syst Rev 2015:CD005049. 17. Tamargo J, Delpón E, Caballero R. The safe- ty of digoxin as a pharmacological treatment of atrial fibrillation. Expert Opin Drug Saf 2006;5:453-467. 18. Kirchhof P, Camm AJ, Goette A, et al; EAST- AFNET 4 Trial Investigators. Early rhythm- control therapy in patients with atrial fibri- llation. N Engl J Med 2020;383:1305–1316. 19. Rillig A, Eckardt L, Borof K, et al. Safety and efficacy of long-term sodium channel blocker therapy for early rhythm control: the EAST- AFNET 4 trial. Europace 2024;26:euae121. 20. Dickow J, Kirchhof P, Van Houten HK, et al. Generalizability of the EAST-AFNET 4 Trial: assessing outcomes of early rhythm-control therapy in patients with atrial fibrillation. J Am Heart Assoc. 2022;11: e024214. 21. Kim D, Yang PS, Joung B. Optimal Rhythm Control Strategy in Patients With Atrial Fi- brillation. Korean Circ J. 2022;52(7):496-512. 22. Burnham TS, May HT, Bair TL, et al. Long- term outcomes in patients treated with flecainide for atrial fibrillation with sta- ble coronary artery disease. Am Heart J 2022;243:127–139. 23. Kiani S, Sayegh MN, Ibrahim R, et al. The feasibility and safety of flecainide use among patients with varying degrees of co- ronary disease. JACC Clin Electrophysiol 2023;9:1172–1180. 24. Singh BN, Singh SN, Reda DJ, et al; Sota- lol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005;352:1861-1872. 25. Allessie M, Ausma J, Schotten U. Electri- cal, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res. 2002;54:230–246. 26. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91:265–325. 27. Heijman J, Algalarrondo V, Voigt N, et al. The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysis. Cardiovasc Res 2016;109:467-479.